Compare Adaptive Biotechnologies Corp (ADPT) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nomura Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Nomura Holdings Inc trades at $9.41 (market cap $27.73B). The key difference: Nomura Holdings Inc is far larger — about 8.3× Adaptive Biotechnologies Corp's market cap, and Nomura Holdings Inc pays a 3.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NMR | |
|---|---|---|
Market Cap | $3.33B | $27.73B |
Sector | Health | Financials |
52-Week High | $22.37 | $9.54 |
52-Week Low | $10.24 | $6.30 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Nomura Holdings (NMR) trades at $9.42, up 3.97% with a bullish technical signal. The stock shows strong fundamentals with record annual profit of $340.74B (20.49% margin) and revenue growth to $1.66T. Recent news highlights CEO pay increase following record performance and US expansion plans. Technical indicators show bullish momentum with RSI at neutral levels, while analyst consensus leans hold-heavy with 66.7% neutral rating.
Outlook remains positive with expanding profitability and strategic acquisitions, though recent earnings misses and rising debt-to-asset ratio (26.25%) present execution risks. The stock trades at attractive valuations (P/E 12.66, P/B 1.19) but faces integration challenges from Macquarie acquisition and geopolitical uncertainties affecting growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
